At a glance
ClinicalIndex Comparison RecordN/AActive· 76,685 enrolled
Drug / intervention
Laboratory Biomarker Analysis +2 moreother
Likely dose
Not stated in record
Key inclusion· 2
- ✓Age 55 to <75 years at randomization
- ✓Willing and able to sign informed consent
Key exclusion· 7
- ✕Current cancer treatment (excluding basal-cell and squamous-cell skin cancer)
- ✕Prior history of prostate, lung, colon, or rectal cancer
- ✕Prior surgical removal of entire prostate, colon, or one lung
- ✕Finasteride use in past 6 months
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
In Brief
A clinical study evaluating Laboratory Biomarker Analysis, Medical Examination Assessment, and 1 other intervention for Prostate Carcinoma. Active but no longer recruiting, targeting 76,685 participants across 1 site.
Detailed Summary
This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for prostate cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Carcinoma
CountriesUnited States
Collaborators--
Timeline
N/AActive
199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
Enrollment StartNov 1993
First PostedMar 2004
Primary CompletionMay 2012
TodayJul 2026
Study CompletionJun 2027
First PostedMar 26, 2004
Enrollment StartNov 16, 1993
Primary CompletionMay 21, 2012
Study CompletionJun 30, 2027
TodayJul 2, 2026
Enrollment to primary: 18.5 yearsPosted 22.3 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Medical Examination Assessmentprocedure
Undergo DRE
Screening Questionnaire Administrationother
Undergo questionnaire assessments